• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pharmaceuticals in Belgium Product Image

Pharmaceuticals in Belgium

  • Published: November 2012
  • Region: Belgium
  • 35 pages
  • MarketLine

Introduction

Pharmaceuticals in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Belgium pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

- The Belgian pharmaceuticals market had total revenues of $6.2 billion in 2011, representing a compound annual growth rate (CAGR) of 3.2% between 2007 and 2011.

- 0

- The performance of the market is forecast to decelerate, with an anticipated CAGR of 1% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $6.5 billion by the end of 2016.

Features

Save time carrying out entry-level research by identifying READ MORE >

Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Geography segmentation 9
Market share 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Pfizer Inc. 20
GlaxoSmithKline Plc 23
AstraZeneca PLC 27
Macroeconomic Indicators 31
Country Data 31
Appendix 33
Methodology 33
Industry associations 34
Related MarketLine research 34

LIST OF TABLES
Table 1: Belgium pharmaceuticals market value: $ billion, 2007–11 8
Table 2: Belgium pharmaceuticals market geography segmentation: $ billion, 2011 9
Table 3: Belgium pharmaceuticals market share: % share, by value, 2011 10
Table 4: Belgium pharmaceuticals market value forecast: $ billion, 2011–16 11
Table 5: Pfizer Inc.: key facts 20
Table 6: Pfizer Inc.: key financials ($) 21
Table 7: Pfizer Inc.: key financial ratios 21
Table 8: GlaxoSmithKline Plc: key facts 23
Table 9: GlaxoSmithKline Plc: key financials ($) 24
Table 10: GlaxoSmithKline Plc: key financials (£) 25
Table 11: GlaxoSmithKline Plc: key financial ratios 25
Table 12: AstraZeneca PLC: key facts 27
Table 13: AstraZeneca PLC: key financials ($) 28
Table 14: AstraZeneca PLC: key financial ratios 29
Table 15: Belgium size of population (million), 2007–11 31
Table 16: Belgium gdp (constant 2000 prices, $ billion), 2007–11 31
Table 17: Belgium gdp (current prices, $ billion), 2007–11 31
Table 18: Belgium inflation, 2007–11 32
Table 19: Belgium consumer price index (absolute), 2007–11 32
Table 20: Belgium exchange rate, 2007–11 32

LIST OF FIGURES
Figure 1: Belgium pharmaceuticals market value: $ billion, 2007–11 8
Figure 2: Belgium pharmaceuticals market geography segmentation: % share, by value, 2011 9
Figure 3: Belgium pharmaceuticals market share: % share, by value, 2011 10
Figure 4: Belgium pharmaceuticals market value forecast: $ billion, 2011–16 11
Figure 5: Forces driving competition in the pharmaceuticals market in Belgium, 2011 12
Figure 6: Drivers of buyer power in the pharmaceuticals market in Belgium, 2011 13
Figure 7: Drivers of supplier power in the pharmaceuticals market in Belgium, 2011 15
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Belgium, 2011 16
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Belgium, 2011 18
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Belgium, 2011 19
Figure 11: Pfizer Inc.: revenues & profitability 22
Figure 12: Pfizer Inc.: assets & liabilities 22
Figure 13: GlaxoSmithKline Plc: revenues & profitability 25
Figure 14: GlaxoSmithKline Plc: assets & liabilities 26
Figure 15: AstraZeneca PLC: revenues & profitability 29
Figure 16: AstraZeneca PLC: assets & liabilities 30

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos